Tefibazumab

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis^[1] and of methicillin-resistant S. aureus.^[2]

Tefibazumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	Clumping factor A
Clinical data
Trade names	Aurexis
ATC code	none
Identifiers
CAS Number	521079-87-8 N
ChemSpider	none
UNII	SBO7Q9G95R
KEGG	D06054 Y
Chemical and physical data
Formula	C6548H10122N1730O2034S44
Molar mass	147035.72 g·mol−1
NY (what is this?)  (verify)

It was developed by Inhibitex.^[3]

See also

• MSCRAMM (microbial surface components recognizing adhesive matrix molecules)